Morepen Laboratories Share Price Gains Over 4%; Enters US Prescription Generics Market with Desloratadine Launch

On November 9, 2026, Morepen Laboratories Limited has informed the stock exchanges regarding its entry into the United States prescription generic pharmaceutical sector, as per the exchange filings.  

The move builds upon the company’s pre-existing active pharmaceutical ingredient manufacturing operations. This expansion represents a commercial transition into finished-dosage medicines and distribution within regulated international markets. 

Launch of Desloratadine Tablets in the United States 

Morepen Laboratories Limited launched its 1st prescription generic product, Desloratadine Tablets USP, 5 mg, in the US market on November 9, 2026. The distribution is being managed by its wholly owned US subsidiary, Morepen Bio Inc. The medicine is supplied in 100-count and 500-count packaging units. 

The company has supplied Desloratadine active pharmaceutical ingredients to the US market for multiple years. This launch extends the operational scope of the firm into finished-dosage forms. The development strategy is led by Sanjay Suri, Managing Director of Morepen Laboratories Limited. 

Regulatory Filings and Product Portfolio Expansion 

The prescription generic rollout follows the previous introduction of over-the-counter products in the US. Separately, the company submitted its 1st Abbreviated New Drug Application to the US FDA for Sitagliptin Phosphate Tablets USP. 

This regulatory application covers 25 mg, 50 mg, and 100 mg strengths of the medicine. The application is under regulatory review by the authorities. The company plans to pursue additional prescription generic filings and distribution channels where its research and active pharmaceutical ingredient lines provide commercial utility. 

Read More: Mphasis Share Price in Focus Post Q2 FY27 Earnings Results: Total Income Up 18.9% YoY! 

Morepen Laboratories Share Price Performance  

As of November 09, 2026, at 10:53 AM, Morepen Laboratories share price on NSE was trading at ₹98.29 up by 4.09% from the previous closing price. 

Conclusion 

Morepen Laboratories Limited entered the US prescription generics market on November 9, 2026, by launching Desloratadine Tablets USP, 5 mg, in 100-count and 500-count packs. The firm also submitted an application for Sitagliptin Phosphate Tablets USP. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.